Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials

Recruiting

Conditions: Multiple Sclerosis

First Posted Date: 2022-03-31

Last Posted Date: 2024-12-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 335

Registration Number: NCT05301907

Locations: 🇨🇭
Novartis Investigative Site, Basel, Switzerland

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

Phase 3

Active, not recruiting

Conditions: Hyperlipoproteinemia(a)

Interventions: Drug: Pelacarsen (TQJ230) 80 mg s.c.
Drug: Corresponding Placebo

First Posted Date: 2022-03-31

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT05305664

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study

Completed

Conditions: PIK3CA-related Overgrowth Spectrum

Interventions: Other: Alpelisib

First Posted Date: 2022-03-24

Last Posted Date: 2024-08-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT05294289

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

A Post Marketing Surveillance on Piqray in Korea

Recruiting

Conditions: Breast Cancer

Interventions: Other: Piqray

First Posted Date: 2022-03-24

Last Posted Date: 2024-12-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 900

Registration Number: NCT05293470

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of

Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study

Recruiting

Conditions: Multiple Sclerosis

Interventions: Other: Ofatumumab

First Posted Date: 2022-03-18

Last Posted Date: 2024-03-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 149

Registration Number: NCT05285904

Locations: 🇨🇭
Novartis Investigative Site, Zurich, Switzerland

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: MGY825

First Posted Date: 2022-03-11

Last Posted Date: 2024-09-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 140

Registration Number: NCT05275868

Locations: 🇺🇸
Wash U School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute ., Boston, Massachusetts, United States

and more 4 locations

First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of EDI048 in Healthy Volunteers

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: EDI048
Other: Placebo

First Posted Date: 2022-03-11

Last Posted Date: 2024-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT05275855

Locations: 🇬🇧
Novartis Investigative Site, Mere Way, Nottingham, United Kingdom

A 24-week rPMS Study in Real-world Setting for Enerzair

Recruiting

Conditions: Asthma

Interventions: Other: Enerzair 150/50/80 μg
Other: Enerzair 150/50/160 μg

First Posted Date: 2022-03-10

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 600

Registration Number: NCT05274425

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of

Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus

Phase 1

Withdrawn

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: MHS552

First Posted Date: 2022-03-09

Last Posted Date: 2023-04-07

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05272059

Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Phase 4

Completed

Conditions: Neovascular Age-related Macular Degeneration (nAMD)

Interventions: Biological: Injection Brolucizumab

First Posted Date: 2022-03-08

Last Posted Date: 2024-12-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 105

Registration Number: NCT05269966

Locations: 🇮🇳
Novartis Investigative Site, New Delhi, India

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy